TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34278040
Drug: DualStim therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: DualStim therapy with intracavernosal injection of Wharton's Jelly (WJ)
Study: 34278040
Drug: DualStim therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: DualStim therapy with saline (control)
Study: 32833109
Drug: N-acetylcysteine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine administration prior to CA procedure
Study: 34867116
Drug: Computer-assisted local
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-assisted local anesthesia injection
Study: 34867116
Drug: Traditional manual
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional manual injection of local anesthesia
Study: 35366801
Drug: EZ-bronchial blocker
Normalized name: Bronchitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EZ-bronchial blocker (EZB)
Study: 32374123
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg solifenacin succinate in the early postoperative period (G1A)
Study: 32374123
Drug: No solifenacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No solifenacin treatment (G1B)
Study: 32374123
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg solifenacin succinate in the early postoperative period (G2A)
Study: 32374123
Drug: No solifenacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No solifenacin treatment (G2B)
Study: 36097258
Drug: Topical benzyl
Normalized name: benzyl alcohol Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical benzyl benzoate (25% or 10%) for daily use over three consecutive days
Study: 36097258
Drug: Oral ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ivermectin (200μg/kg body weight) twice, one week apart
Study: 36097258
Drug: Topical benzyl
Normalized name: benzyl alcohol Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical benzyl benzoate (25% or 10%) upon repeated application
Study: 36097258
Drug: Oral ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ivermectin upon repeated application
Study: 36097258
Drug: Topical benzyl
Normalized name: benzyl alcohol Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical benzyl benzoate upon repeated application
Study: 36097258
Drug: Topical benzyl
Normalized name: benzyl alcohol Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical benzyl benzoate
Study: 33313736
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of self-care CIH therapies (tai chi/qi gong, yoga, meditation) and practitioner-delivered CIH therapies (chiropractic care, acupuncture, therapeutic massage)
Study: 33313736
Drug: Practitioner-delivered CIH
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practitioner-delivered CIH therapies alone (chiropractic care, acupuncture, therapeutic massage)
Study: 33313736
Drug: Self-care CIH
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-care CIH therapies alone (tai chi/qi gong, yoga, meditation)
Study: 34783204
Drug: HIPEC (hyperthermic
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIPEC (hyperthermic intraperitoneal chemotherapy) at 42°C (41.5°C‐42.5°C)
Study: 34783204
Drug: NIPEC (normothermic
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIPEC (normothermic intraperitoneal chemotherapy) at 37°C (36.5°C‐37.5°C)
Study: 34326185
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (4,000 IU) plus low-dose inhaled fluticasone propionate
Study: 32434996
Drug: OIL (1.18
Approvals — FDA: no, EMA: no, PMDA: no
Description: OIL (1.18 g/kg, rich in MUFA)
Study: 35439029
Drug: Navicixizumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navicixizumab (3 mg/kg or 4 mg/kg once every 2 weeks) plus Paclitaxel (80 mg/m2 intravenously on days 0, 7, and 14 of 28-day cycles)
Study: 32095887
Drug: MindMotion™GO exergame
Approvals — FDA: no, EMA: no, PMDA: no
Description: MindMotion™GO exergame therapy for 30 minutes
Study: 35075067
Drug: Experimental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental treatment using a BCI prototype with audio-visual entrainment
Study: 38652999
Drug: Cenobamate 200
Normalized name: cenobamate 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenobamate 200 mg/day
Study: 35182037
Drug: Cenobamate 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenobamate 500 mg/day
Study: 34283380
Drug: Daily micro-surveys
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily micro-surveys administered via smartphone application
Study: 34283380
Drug: Full-length SF-36
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-length SF-36 administered preoperatively and at 4, 12, and 24 weeks postoperatively
Study: 34283380
Drug: Daily micro-surveys
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily micro-surveys
Study: 34849019
Drug: 40mg chloroprocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg chloroprocaine with 5 mcg spinal dexmedetomidine (Spinal Dexgroup)
Study: 34849019
Drug: 40mg chloroprocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg chloroprocaine with 0.5 mcg/kg IV dexmedetomidine (IV DEXgroup)
Study: 34564744
Drug: Radiomics signature
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Radiomics signature based on pre-treatment CT scans
Study: 36494261
Drug: Full-dose S1
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose S1
Study: 36494261
Drug: Reduced-dose S1
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced-dose S1 + oxaliplatin
Study: 33127634
Drug: Study definition
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study definition of hyperkalaemia (serum potassium >5.5 mEq/L)
Study: 33127634
Drug: Study definition
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study definition of hypokalaemia (serum potassium <3.5 mEq/L)
Study: 33127634
Drug: Higher serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher serum potassium associated with estimated glomerular filtration rate <60 mL/min/1.73 m2
Study: 33103819
Drug: Ketogenic medium
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketogenic medium chain triglyceride (kMCT) drink; 15 g twice/day
Study: 35126621
Drug: Traditional oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional oxygen therapy
Study: 32164382
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of synbiotic treatment with DVB-PVP HD
Study: 36147581
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (combined formulations containing ethinyl estradiol 10-35 ug/day plus a synthetic progestin) during the active phase of OC use.
Study: 36147581
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (combined formulations containing ethinyl estradiol 10-35 ug/day plus a synthetic progestin) during the inactive phase of OC use.
Study: 36147581
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives containing first- or second-generation progestins (the estrane family of progestins or OCs containing levonorgestrel).
Study: 36147581
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives containing recently developed progestins and lower doses of ethinyl estradiol.
Study: 36147581
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (various brands classified by estrogenic strength).
Study: 32643265
Drug: Sub-threshold nano-second
Normalized name: DAB(SUB 389)IL2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub-threshold nano-second laser (SNL) treatment
Study: 36205250
Drug: Slurry applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Slurry applied immediately to stubble (63,250 L/ha)
Study: 36205250
Drug: Slurry applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Slurry applied after a 1-wk delay (57,484 L/ha)
Study: 33599975
Drug: Blonanserin transdermal
Normalized name: Blonanserin
DrugBank: Blonanserin (DB09223)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Blonanserin transdermal patch
Study: 36372315
Drug: TrAsU (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TrAsU (treatment as usual, n = 44)
Study: 36221341
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (acupuncture and moxibustion)
Study: 32233095
Drug: Daunorubicin (DNR,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daunorubicin (DNR, 50 mg/m2) with standard-dose cytarabine and etoposide for induction chemotherapy and intermediate dose cytarabine for consolidation
Study: 32233095
Drug: Mitoxantrone (MXR,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone (MXR, 12 mg/m2) with standard-dose cytarabine and etoposide for induction chemotherapy and intermediate dose cytarabine for consolidation
Study: 32233095
Drug: Idarubicin (IDA,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarubicin (IDA, 10 mg/m2) with standard-dose cytarabine and etoposide for induction chemotherapy and intermediate dose cytarabine for consolidation
Study: 34099268
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (30-minute session)
Study: 32962593
Drug: 0.5 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg.kg‐1 ketamine (group K1)
Study: 32962593
Drug: 1 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg.kg‐1 ketamine (group K2)
Study: 33991085
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy for targeted‐therapy related fatigue (CBT‐TTF) delivered via FaceTime for iPad
Study: 34174128
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose multi-strain probiotic De Simone formulation (112.5 billion viable lyophilized bacteria per capsule) for 3 months
Study: 33600826
Drug: PACAP38 infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PACAP38 infusion (10 pmol/kg/minute)
Study: 33600826
Drug: PACAP38 infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PACAP38 infusion (10 pmol/kg/minute) followed by sumatriptan (4 mg)
Study: 33600826
Drug: PACAP38 infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PACAP38 infusion (10 pmol/kg/minute) followed by placebo (saline)
Study: 35100758
Drug: Nasal‐oral aspirator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal‐oral aspirator
Study: 33774765
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care services (PC)
Study: 34097856
Drug: Therapeutic anticoagulation
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic anticoagulation (in-hospital oral rivaroxaban 20 mg or 15 mg daily for stable patients, or initial subcutaneous enoxaparin 1 mg/kg twice per day or intravenous unfractionated heparin for clinically unstable patients, followed by rivaroxaban to day 30)
Study: 34097856
Drug: Prophylactic anticoagulation
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic anticoagulation (standard in-hospital enoxaparin or unfractionated heparin)
Study: 36100826
Drug: Ultrasound-guided transversus
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided transversus abdominis plane block (TAPB) with 20 mL 0.5% ropivacaine and patient-controlled intravenous analgesia (PCIA)
Study: 36100826
Drug: Patient-controlled intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled intravenous analgesia (PCIA) alone
Study: 34077237
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with FOLFOX followed by chemoradiation
Study: 34077237
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with CP followed by chemoradiation
Study: 34473085
Drug: Detecting and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detecting and validating water molecules and metal ions in maps
Study: 32211953
Drug: Mild ovarian
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild ovarian stimulation (MS) using letrozole/antagonist protocol
Study: 32211953
Drug: Conventional controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional controlled ovarian stimulation (COS) using high dose gonadotropin (Gn) and GnRH-a stop protocol
Study: 33045287
Drug: Mirabegron (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron (25 mg, increased to 50 mg after 4 weeks)
Study: 35277398
Drug: Myo-inositol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myo-inositol (2 g twice daily until delivery)
Study: 35277398
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 g twice daily until delivery)
Study: 33813110
Drug: Hydroxychloroquine (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine (800 mg on day 0 followed by 400 mg per day for 8 days)
Study: 34549408
Drug: Inhaling essential
Normalized name: Eucalyptus essential oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaling essential oil (Lavandula angustifolia 0.1 ml + citrus bergamia 0.1 ml) for 28 days
Study: 34653425
Drug: Plenvu (1L
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plenvu (1L polyethylene glycol-based bowel preparation)
Study: 34519561
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 40 mg, oral
Study: 33136231
Drug: Weekly nanoparticle
Normalized name: Doxorubicin nanoparticles
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly nanoparticle albumin‐bound paclitaxel (nab‐PTX)
Study: 33136231
Drug: Weekly solvent‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly solvent‐based paclitaxel (Sb‐PTX)
Study: 34736731
Drug: Rivaroxaban plus
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban plus antiplatelet therapy
Study: 32062444
Drug: fampridine‐MR 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: fampridine‐MR 10 mg bd
Study: 33478179
Drug: Personalized oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized oral health education program in combination with routine dental care
Study: 33478179
Drug: Personalized oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized oral health education program
Study: 32270639
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment group (acupuncture at the 'thirteen ghost points' and kaixin powder)
Study: 32270639
Drug: Chinese medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medication group (kaixin powder only)
Study: 33485159
Drug: Conventional Class
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Class (CC)
Study: 92313688
Drug: Norfloxacin 400
Normalized name: norfloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin 400 mg/24 h for 7 days (Group I)
Study: 92313688
Drug: Norfloxacin 400
Normalized name: norfloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin 400 mg/12 h for 7 days (Group II)
Study: 35966022
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate (CrM) supplementation (0.1 g·kg‐1·day‐1)
Study: 33131908
Drug: 320 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 320 mg/day anthocyanins
Study: 35321886
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride infusion (placebo)
Study: 33593886
Drug: Neoadjuvant PD-L1
Normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Neoadjuvant PD-L1 inhibition in combination with chemotherapy
Study: 33900515
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone (400 mg every day)
Study: 32348531
Drug: Intravitreal corticosteroid
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal corticosteroid implants
Study: 32747361
Drug: Low-dose afabicin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose afabicin (i.v. 80 mg, followed by oral 120 mg, BID)
Study: 32747361
Drug: High-dose afabicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose afabicin (i.v. 160 mg, followed by oral 240 mg, BID)
Study: 32747361
Drug: Vancomycin/linezolid (i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin/linezolid (i.v. vancomycin 1 g or 15 mg/kg, followed by oral linezolid 600 mg, BID)
Study: 34444281
Drug: Modified-active release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified-active release therapy (mART)
Study: 32356413
Drug: expedited oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: expedited oral feeding
Study: 32473365
Drug: Mangifera indica
Normalized name: MANGIFERA INDICA SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mangifera indica leaf extract (MLE), 500 mg orally
Study: 35643952
Drug: 10-day sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day sequential treatment for H. pylori eradication
Study: 33226202
Drug: Protocol B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol B (90 kVp, reduced radiation and standard CM dose)
Study: 33226202
Drug: Protocol C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol C (90 kVp, standard radiation and reduced CM dose)
Study: 33670235
Drug: Multidisciplinary Assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary Assessment and Treatment including ACT (TEAM)
Study: 33670235
Drug: Control (Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Treatment as Usual)
Study: 36432436
Drug: Nutraceutical group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutraceutical group (MHD plus nutraceutical supplementation: Vitamin E, L-glutathione, silymarin, and hepato-active compounds)
Study: 34817396
Drug: Midazolam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (2 mg intravenously)
Study: 36284288
Drug: Glycopyrrolate (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate (0.2 mg IV)
Study: 33765358
Drug: PF-06410293 (adalimumab-afzb)
Normalized name: adalimumab-afzb
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PF-06410293 (adalimumab-afzb) administered by prefilled syringe (PFS)
Study: 33765358
Drug: PF-06410293 (adalimumab-afzb)
Normalized name: adalimumab-afzb
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PF-06410293 (adalimumab-afzb) administered by prefilled pen (PFP)
Study: 35965182
Drug: 2-mA anodal
Normalized name: Zhi ma oil
DrugBank: Sesame oil (DB11172)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-mA anodal 20-minute tDCS over the left primary motor cortex, administered three consecutive sessions every month for five months
Study: 35028171
Drug: Comfrey ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comfrey ointment
Study: 35180097
Drug: Oral Aceclofenac
Normalized name: aceclofenac
DrugBank: Aceclofenac (DB06736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Aceclofenac sustained-release tablets, calcium carbonate and vitamin D3 tablets
Study: 32040183
Drug: List experiment
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: List experiment method (treatment group)
Study: 32682507
Drug: Heated fennel
Normalized name: Fennel
DrugBank: Fennel (DB15615)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heated fennel therapy
Study: 36397122
Drug: 12 sessions
Normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 sessions of concurrent PCC ISF up‐training and dorsal anterior cingulate cortex (dACC) ISF‐NFB down‐training (n=15)
Study: 33498640
Drug: Low sodium
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low sodium meal plan (0.9 mg/kcal)
Study: 33498640
Drug: Typical sodium
Normalized name: benzocaine Mucous Membrane Topical Solution [Topicale]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typical sodium meal plan (2 mg/kcal)
Study: 32285223
Drug: AT13148 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AT13148 treatment in BT474 and PC3 cells
Study: 32285223
Drug: AT13148 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AT13148 treatment in non-tumor bearing mice
Study: 32285223
Drug: AT13148 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AT13148 treatment in patients at doses of 160-300 mg
Study: 34444656
Drug: Caffeine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (6 mg/kg of body mass)
Study: 36201455
Drug: 100 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g/day of fermented vegetables (group A)
Study: 36201455
Drug: 100 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g/day pickled vegetables (group B)